Acucela Issues Notice of Listing Approval of Kubota Pharmaceutical Holdings

SEATTLE--(BUSINESS WIRE)--Acucela Inc. (Tokyo:4589) (the “Company”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, hereby gives notice that the merger agreement regarding its proposed redomicile transaction was adopted at the Annual Meeting of Shareholders of the Company held on October 18, 2016 Pacific Time in Seattle, Washington. Upon the completion of the mer